We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.
Health conditions and diseases that the clinical trial is designed to study and treat.
Aggressive Large B-Cell Lymphoma (DLBCL) is a fast-growing type of non-Hodgkin lymphoma that affects B-cells, a type of white blood cell. Patients with relapsed or refractory DLBCL have not responded to initial treatments and are at high risk of further disease progression.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.